Cagent Vascular is participating in the VIVA 2026 lunch symposium on serration remodeling therapy across PAD and AVF interventions, including final results from the POINT FORCE Registry.

Cagent Vascular is the first and only company to commercialize an angioplasty balloon with integrated serrations, introducing a new category of endovascular treatment: Serration Remodeling Therapy (SRT). Headquartered in Wayne, PA, our mission is to improve outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) by changing the way physicians treat diseased vessels. Our flagship device, the Serranator® PTA Serration Balloon Catheter, creates controlled micro-fissures in the arterial wall, driving vessel wall remodeling, not just dilation. The result: greater lumen gain, reduced recoil, and improved vessel compliance across lesion morphologies. It's time for a new standard of care. It starts with Serranator.